Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

A Phase Ib/II Open-Label, Multicentre Platform Study Evaluating Novel Combinations in Participants with Advanced or Metastatic Non-Small Cel… Pending

2024-519786-22-01 metastatic non-small cell lung cancer (NSCLC) 9
A Trial to Study if REGN17372 in Combination with Linvoseltamab is Tolerable for Adult Participants with Relapsed/Refractory Multiple Myelom… Pending

2025-522776-93-00 Relapsed/Refractory Multiple Myeloma 1
A study of pelabresib and ruxolitinib compared to placebo and ruxolitinib in adult patients with myelofibrosis who have not received prior t… Pending

2025-523555-66-00 Myelofibrosis 5
GRAIN, Prospective Pilot Study Pending

2025-524470-41-00 Esophageal adenocarcinoma 1
Phase I-II prospective trial, multicenter, open label, exploring the combination of Trabectedin plus RAdiotherapy in Soft Tissue Sarcoma pat… Pending

2024-518199-30-00 Soft tissue sarcoma patients 9
A phase 1b study of an autologous dendritic cell immunotherapy in combination with anti-programmed death-1 treatment in patients with metast… Pending

2025-521577-13-00 metastatic non-small-cell lung cancer 1
STAMPEDE2: A randomised controlled platform trial testing treatments in metastatic hormone sensitive prostate cancer Pending

2025-522145-21-00 Metastatic hormone sensitive prostate cancer 5
PREDICTION OF COMPLICATIONS IN PATIENTS UNDERGOING SURGICAL TREATMENT OF HEPATIC TUMORS Pending

2025-524477-17-00 Hepatic tumor 6
SIOP PNET 5 medulloblastoma Pending

2024-513724-42-00 Medulloblastoma 10
A PHASE 1/1B, OPEN-LABEL, MULTICENTER, FIRST-IN-HUMAN DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMAC… Pending

2025-522148-42-00 Advanced Solid Tumours 1
Hyperprogression upon cemiplimab alone or with chemotherapy in PD-L1 ≥ 50% NSCLC: a biomarker guided phase 2 trial – HYPERBOLIC study Pending

2025-521583-35-00 non-small cell lung cancer (NSCLC) 4
A study to evaluate the safety and efficacy of the tumor-targeting human antibody-cytokine fusion protein L19TNF plus standard temozolomide … Pending

2024-516357-46-00 Glioblastoma 9
A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizu… Pending

2025-521587-35-00 Metastatic colorectal cancer 5
Trial assessing treatment in patients with advanced Lung Cancer and Interstitial Lung Disease Pending

2025-522790-10-00 Non Small Cell Lung Cancer 4
Phase II study of ezabenlimab in patients with PD-L1-positive head and neck cancer with residual disease detected by ctDNA after chemoradiot… Pending

2025-523575-36-00 Locally advanced head and neck squamous cell carcinoma 4
A clinical trial to learn about the effects of DAK539 on the blood levels of repaglinide, midazolam, drospirenone, and ethinyl estradiol in … Pending

2025-521000-22-00 Patients with advanced malignancies 3
A Study of LY4064809 With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) Pending

2025-522791-92-00 Neoplasm Metastasis 5
A Study of Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants with Unresectable Stage III NSCLC Pending

2025-523576-23-00 Unresectable Stage III non-small cell lung cancer witho 5
A trial to learn how safe durvalumab with chemotherapy is and how well it works in adults with muscle-invasive bladder cancer Pending

2024-519246-75-01 Patients With Muscle-Invasive Bladder Cancer 4
A clinical trial to learn how liver function affects the blood levels of DAK539 in people with advanced cancer Pending

2025-521001-40-00 Advanced Malignancies and Hepatic Impairment 3
A Study of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50% Pending

2025-523586-18-00 Non-Small Cell Lung Cancer 5
Guided by Light: Optimizing Surgical Excision of Oral Cancer Using Realtime Fluorescence Imaging Pending

2024-512824-13-01 Oral cancer 7
THRILL: Treat Hyperinflammation in child oncology study Pending

2025-524541-27-00 Hyperinflammation 4
ETCABio - Evaluation of Skin Tests in Biotherapy Allergies Pending

2024-519812-15-00 deficient mismatch repair (dMMR) colorectal cancer 6